• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

第 25 届加拿大西部胃肠道癌症共识会议关于胃癌和胃食管交界癌的报告，温尼伯，曼尼托巴省，2023 年 10 月 26-27 日。

Report from the 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Gastric and Gastroesophageal Cancers, Winnipeg, Manitoba, 26-27 October 2023.

机构信息

CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.

Western Manitoba Cancer Center, Brandon, MB R7A 5M8, Canada.

出版信息

Curr Oncol. 2024 Oct 7;31(10):5987-6006. doi: 10.3390/curroncol31100447.

DOI:10.3390/curroncol31100447
PMID:39451751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11505746/
Abstract

The 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Winnipeg, Manitoba, on 26-27 October 2023. The WCGCCC is an interactive multidisciplinary conference that was attended by healthcare professionals from across Western Canada (British Columbia, Alberta, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; oncology nurses; pharmacists; and a family physician in oncology (FPO) participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of gastroesophageal cancers.

摘要

第 25 届加拿大西部胃肠道癌症共识会议（WCGCCC）于 2023 年 10 月 26-27 日在曼尼托巴省温尼伯市举行。WCGCCC 是一个互动的多学科会议，来自加拿大西部（不列颠哥伦比亚省、艾伯塔省和马尼托巴省）的医疗保健专业人员参加了会议，他们参与了胃肠道癌症患者的护理。外科医生、内科医生、肿瘤放射科医生；病理学家；肿瘤护士；药剂师；以及肿瘤学家庭医生（FPO）参加了演讲和讨论会议，旨在制定这里提出的建议。本共识声明涉及胃食管癌症管理中的当前问题。

相似文献

1
Report from the 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Gastric and Gastroesophageal Cancers, Winnipeg, Manitoba, 26-27 October 2023.第 25 届加拿大西部胃肠道癌症共识会议关于胃癌和胃食管交界癌的报告，温尼伯，曼尼托巴省，2023 年 10 月 26-27 日。
Curr Oncol. 2024 Oct 7;31(10):5987-6006. doi: 10.3390/curroncol31100447.
2
Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.第19届加拿大西部胃肠癌共识会议报告；马尼托巴省温尼伯；2017年9月29日至30日。
Curr Oncol. 2018 Aug;25(4):275-284. doi: 10.3747/co.25.4109. Epub 2018 Aug 14.
3
Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17-18 October 2024.第26届加拿大西部胃肠癌肝细胞癌和胆管癌年度共识会议报告，萨斯喀彻温省萨斯卡通，2024年10月17 - 18日。
Curr Oncol. 2025 Jul 10;32(7):398. doi: 10.3390/curroncol32070398.
4
Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28-29, October 2022.第 24 届加拿大西部胃肠道癌症共识会议关于结直肠癌的年度报告，2022 年 10 月 28-29 日，不列颠哥伦比亚省里士满。
Curr Oncol. 2023 Aug 29;30(9):7964-7983. doi: 10.3390/curroncol30090579.
5
Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019.第 21 届加拿大西部胃肠道癌症共识会议报告；艾伯塔省卡尔加里；2019 年 9 月 20-21 日。
Curr Oncol. 2021 Sep 21;28(5):3629-3648. doi: 10.3390/curroncol28050310.
6
Report from the Western Canadian Gastrointestinal Consensus Cancer Conference-Management of Total Neoadjuvant Therapy in Rectal Cancer.加拿大西部胃肠道共识癌症会议报告-直肠癌新辅助放化疗的全程管理。
Curr Oncol. 2022 Feb 8;29(2):924-927. doi: 10.3390/curroncol29020078.
7
Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015.第17届加拿大西部胃肠道癌年度共识会议报告；艾伯塔省埃德蒙顿；2015年9月11 - 12日
Curr Oncol. 2016 Dec;23(6):425-434. doi: 10.3747/co.23.3384. Epub 2016 Dec 21.
8
Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018.第 20 届加拿大西部胃肠癌症共识会议报告；萨斯卡通，萨斯喀彻温省；2018 年 9 月 28 日至 29 日。
Curr Oncol. 2019 Dec;26(6):e773-e784. doi: 10.3747/co.26.5517. Epub 2019 Dec 1.
9
Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.可切除性肝转移结直肠癌患者的全身治疗及其手术意义。来自加拿大西部胃肠道癌症共识会议的报告。
Curr Oncol. 2022 Mar 8;29(3):1796-1807. doi: 10.3390/curroncol29030147.
10
Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC.加拿大西部胃肠癌共识会议虚拟教育系列报告-从局部治疗向系统治疗的过渡和 HCC 系统治疗的最佳序贯。
Curr Oncol. 2021 Oct 29;28(6):4317-4327. doi: 10.3390/curroncol28060367.

本文引用的文献

1
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.新辅助和辅助帕博利珠单抗联合化疗治疗局部晚期胃或胃食管交界癌（KEYNOTE-585）：多中心、双盲、随机 3 期研究的中期分析。
Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19.
2
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.帕博利珠单抗联合曲妥珠单抗和化疗治疗 HER2 阳性胃或胃食管交界腺癌：来自 3 期 KEYNOTE-811 随机安慰剂对照试验的中期分析。
Lancet. 2023 Dec 9;402(10418):2197-2208. doi: 10.1016/S0140-6736(23)02033-0. Epub 2023 Oct 20.
3
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.三联疗法与围手术期化疗治疗局部晚期食管及食管胃交界腺癌（Neo - AEGIS）：一项开放标签、随机、3期试验
Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. doi: 10.1016/S2468-1253(23)00243-1. Epub 2023 Sep 18.
4
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases.原发性胃腺癌及配对转移灶中程序性死亡配体1（PD-L1）的表达
J Cancer Res Clin Oncol. 2023 Nov;149(14):13345-13352. doi: 10.1007/s00432-023-05142-x. Epub 2023 Jul 25.
5
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.曲妥珠单抗 deruxtecan 用于美国和欧洲的曲妥珠单抗治疗后疾病进展的 HER2 阳性晚期胃或胃食管交界处癌患者（DESTINY-Gastric02）：一项单臂、2 期研究的主要和更新分析。
Lancet Oncol. 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14.
6
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.zolbetuximab 联合 mFOLFOX6 治疗 Claudin18.2 阳性、HER2 阴性、未经治疗的局部晚期不可切除或转移性胃或胃食管结合部腺癌患者（SPOTLIGHT）：一项多中心、随机、双盲、III 期临床试验。
Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15.
7
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.采用联合阳性评分评估胃、胃食管交界部和食管腺癌 PD-L1 表达时，病理学家之间存在高度观察者间变异性。
Mod Pathol. 2023 May;36(5):100154. doi: 10.1016/j.modpat.2023.100154. Epub 2023 Mar 15.
8
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.多机构研究病理学家对胃癌或胃食管结合部癌程序性细胞死亡配体-1 联合阳性评分免疫组织化学检测的解读。
Mod Pathol. 2023 May;36(5):100128. doi: 10.1016/j.modpat.2023.100128. Epub 2023 Feb 13.
9
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.Neo-PLANET 二期临床试验：新辅助卡瑞利珠单抗联合放化疗治疗局部晚期胃或胃食管结合部腺癌。
Nat Commun. 2022 Nov 10;13(1):6807. doi: 10.1038/s41467-022-34403-5.
10
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.贝伐珠单抗治疗 FGFR2b 选择的胃或胃食管结合部腺癌患者（FIGHT）：一项随机、双盲、安慰剂对照、2 期研究。
Lancet Oncol. 2022 Nov;23(11):1430-1440. doi: 10.1016/S1470-2045(22)00603-9. Epub 2022 Oct 14.